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An Expressed Retrogene of the Master
Embryonic Stem Cell Gene POU5F1
Is Associated with Prostate Cancer Susceptibility
Joan P. Breyer,1 Daniel C. Dorset,1 Travis A. Clark,1 Kevin M. Bradley,1,2 Tiina A. Wahlfors,3
Kate M. McReynolds,1 William H. Maynard,1 Sam S. Chang,4 Michael S. Cookson,4 Joseph A. Smith,4
Johanna Schleutker,5 William D. Dupont,6 and Jeffrey R. Smith1,7,*
Genetic association studies of prostate and other cancers have identified a major risk locus at chromosome 8q24. Several independent
risk variants at this locus alter transcriptional regulatory elements, but an affected gene and mechanism for cancer predisposition have
remained elusive. The retrogene POU5F1B within the locus has a preserved open reading frame encoding a homolog of the master
embryonic stem cell transcription factor Oct4.We find that 8q24 risk alleles are expression quantitative trait loci correlated with reduced
expression of POU5F1B in prostate tissue and that predicted deleterious POU5F1Bmissense variants are also associated with risk of trans-
formation. POU5F1 is known to be self-regulated by the encoded Oct4 transcription factor.We further observe that POU5F1 expression is
directly correlated with POU5F1B expression. Our results suggest that a pathway critical to self-renewal of embryonic stem cells may also
have a role in the origin of cancer.Introduction
Genome-wide association studies (GWASs) have identified
a key locus at 8q24 that is associated with risk for
numerous cancers, including prostate, colon, ovarian,
breast, and bladder cancer, as well as chronic lympho-
cytic leukemia (MIM 176807, 114500, 167000, 114480,
109800, and 151400, respectively). Prostate cancer is the
most prominent among them, with risk-associated SNPs
spanning a 615 kb interval that is subdivided into several
linkage disequilibrium (LD) blocks. The prostate cancer
risk associations are observed in populations of European,
Asian, and African descent. There are 24 prostate cancer
risk SNPs in the interval that have been reported in the
literature, some correlated by LD patterns in a given pop-
ulation. This region is a relative gene desert, encompassing
four noncoding RNA genes (PCAT1, PRNCR1 [MIM
615452], CCAT1, and CASC8) and POU5F1B. POU5F1B is
a retrotransposed processed copy of the gene encoding
the master embryonic stem cell factor Oct4. POU5F1B
has an intact open reading frame (ORF) with 96% identity
to Oct4 isoform 1 and is transcribed in multiple cancers,
including prostate cancer.1–4 Some risk variants are in
LD with SNPs within these genes, which could in turn
have a role in cancer initiation.1,5–10 Other risk variants
alter (or are in LD with variants that alter) regional
transcriptional regulatory elements, which could affect
cancer risk by influencing the expression of an adjacent
gene, or another at a distance from the locus. Genes
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Of the genes within and flanking the 8q24 risk locus,
only POU5F1B, PCAT1, and CASC8 are in LD with known
GWAS SNPs. GWAS SNPs rs6983267, rs7000448, and
rs10808556 are in LD with variants of the POU5F1B ORF
among people of European descent. These SNPs are associ-
ated with prostate, colon, and ovarian cancer.11–19 Given
the retrotransposition event, POU5F1B expression would
be dependent upon existing regional transcriptional regu-
latory elements that may be active in a given tissue or state.
POU5F1B transcription start sites have been described
spanning 860 kb, a span encompassing 17 GWAS risk var-
iants of the 8q24 locus.1 Start sites and alternative 50 UTR
exons across this region are well supported by RNA-seq
data of both normal and tumor prostate tissue from The
Cancer Genome Atlas (TCGA) Project. Additional 8q24
GWAS SNPs are in LD with PCAT1 and CASC8 (PCAT1 is
in LD with rs10086908; CASC8 is in LD with rs1447295,
rs11995378, rs4242382, rs4242384, rs10090154, and
rs7837688).11,13,14,17,20–27 Thus, patterns of linkage
disequilibrium with the GWAS-identified risk variants
identify POU5F1B, PCAT1, and CASC8 as candidate pros-
tate cancer susceptibility genes.
Three transcriptional regulatory elements have been
described within the 8q24 locus that are each func-
tionally altered either by GWAS SNPs or by SNPs in LD
with them.28–35 Correlation of GWAS SNPs with expres-
sion could identify a target gene as a candidate cancer-
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Table 1. Familial Prostate Cancer Study
Control Subjects Case Subjects
Total (no.) 930 928
European descent (no.) 830 865
African descent (no.) 100 63
Mean agea (years) 60.1 60.1
Mean no. brothers 1.8 1.7
Median PSAa 0.9 5.5
Age % 60 at diagnosis (no.) – 470
Age R 61 at diagnosis (no.) – 458
Gleason sum% 6 (no.) – 469
Gleason sumR 7 (no.) – 427
0 affected in pedigreeb (no.) 930 –
2 affected in pedigreeb (no.) – 575
R3 affected in pedigreeb (no.) – 353
aAt diagnosis for case subjects, at screen for control subjects
bProband plus first and second degree affected relativesGWAS-detected regulatory elements at 8q24 in cancer risk,
with constitutional variants influencing expression of an
affected gene or genes, the identity of which has remained
unknown.
We investigated whether GWAS SNPs at 8q24 alter
POU5F1B expression in normal or cancerous prostate tissue
and whether POU5F1B genetic variants alter prostate can-
cer risk. The parent gene at 6p21, POU5F1 (MIM 164177)
(also known as OCT4), is not expressed in differentiated
adult somatic cells but is one of a few known genes that
may be manipulated to create an induced pluripotent
stem cell from such a cell.36–38 In expression construct
tests, Pou5f1b localizes to the nucleus and retains tran-
scriptional activity.39 When ectopically overexpressed in
mice, Oct4 causes epithelial cell dysplasia and expansion
of a compartment of undifferentiated cells.40 In light of
the stem cell hypothesis of cancer initiation, POU5F1B is
an intriguing candidate cancer-susceptibility gene within
the 8q24 locus.41Subjects and Methods
US Study Population
We initiated the Familial Prostate Cancer Study (FPCS) as an
observational hospital-based study of familial prostate cancer at
Vanderbilt Medical Center in 2003. The FPCS is among the largest
case-control studies of familial prostate cancer (Table 1). We re-
cruited incident familial prostate cancer probands (R2 affected
first or second degree relatives in the pedigree) at the time of treat-
ment for the principal diagnosis of prostate cancer (confirmed by
review of pathology) and control probands at the time of routine
preventative screening for prostate cancer. Control subjects had
no personal or family history of prostate cancer (first and second
degree relatives), no known prostate-specific antigen (PSA)396 The American Journal of Human Genetics 94, 395–404, March 6>4 ng/dl or abnormal digital rectal exam, and no history of pros-
tate biopsy. This familial study design provides improved power to
detect genetic risk variants.42 Approximately 95% of eligible sub-
jects agreed to participate. We matched case subjects to control
subjects in a 1:1 ratio by race and age, within 2.5 years of age at
diagnosis or screen. A small excess of familial subjects remained
unmatched to control subjects in the ongoing study. All subjects
completed a structured questionnaire of family cancer history, de-
mographics, and ancestry. The date, age, and PSA level at diagnosis
of adenocarcinoma or at screen was recorded for each subject. The
initial clinical staging (clinical TNM), biopsy Gleason score, treat-
ment modality, and date(s) were recorded. More than 97% of
affected subjects underwent radical prostatectomy, providing
definitive histopathologic diagnoses. For these, surgical pathology
staging (pathological TNM), seminal vesicle invasion, margin sta-
tus, left and right lobe Gleason scores and sum, and capsular pene-
tration were recorded. Among familial subjects of European
descent with available pathologic staging, 175 of 844 (21%) were
of pT3, pT4, N1, or M1 stage. The study was conducted in accor-
dance with the protocol approved by the governing Institutional
Review Board, with written informed consent of human subjects.Finnish Study Population
Unselected individuals were collected in the Pirkanmaa Hospital
District, totaling 934 subjects. In addition to the unselected indi-
viduals, 190 case probands of Finnish prostate cancer families
were included. The collection of the Finnish prostate cancer sam-
ples and families has been described previously.43,44 These families
had at least two members affected by prostate cancer. All 923 con-
trol subjects consisted of population-matched healthy individuals
of ages between 18 and 65 years. The blood DNA samples (anony-
mous male blood donors) were obtained from the Finnish Red
Cross Blood Transfusion service. The study was governed by the
Ethics Committees of the Tampere University Hospital, Finland,
as well as the Ministry of Social Affairs and Health in Finland,
with written informed consent of human subjects.Sequencing and Genotyping
DNA was extracted from whole blood on an Autopure LS robot
via the Puregene DNA Purification System Standard Protocol
(QIAGEN). DNAwas quantified with the PicoGreen dsDNA Quan-
titation Kit (Invitrogen), imaged with a Molecular Devices/LJL
Analyst HT (Molecular Devices). A 1.9 kb region encompassing
POU5F1B was amplified from genomic DNA by unique flanking
priming sites with the Expand Long Template PCR System
(Roche). Sanger sequencing assays used as template the long-range
PCR product. TaqMan genotyping assays (Life Technologies) used
as template the long-range PCR product diluted 1:100K-fold to
reduce carry-over genomic template to nonamplifiable levels,
while retaining the ability to amplify from the long-range PCR
product. Regional 8q24 GWAS SNPs were genotyped as TaqMan
assays from genomic DNA. POU5F1B assay primers are provided
in Table S1 available online. All genotype data were in Hardy-
Weinberg equilibrium among control subjects.The Cancer Genome Atlas Data Set
We selected the set of 44 subjects with available data for both
normal prostate tissue and prostate tumor tissue, as well as the
set of 132 subjects with available data for prostate tumor tissue
from The Cancer Genome Atlas (TCGA). Of the 44 subjects
with normal and tumor tissue data, 33 were designated as white,, 2014
4 were black, and 7 had no designation. Of the 132 subjects with
only tumor tissue data, 103 were white, 3 were black, 2 were Asian,
and 24 were not designated. Because GWASs implicating the
8q24 locus in cancer risk have been predominantly conducted
in populations of European descent, our primary analyses were
conducted in the TCGA subjects designated as white. For each of
these subjects, we accessed TCGA germline genotype data from
blood and/or normal tissue (Affymetrix Genome_Wide_SNP_6),
somatic copy number measures from tumor (GISTIC2, Affymetrix
Genome_Wide_SNP_6), methylation measures from normal and
tumor (Illumina HumanMethylation450), and RSEM normalized
gene expression measures of normal and tumor (IlluminaHiSeq_
RNASeqV2).
Statistical Analysis
We tested the association of 8q24 GWAS SNPs and POU5F1B vari-
ation with prostate cancer based upon either single alleles or hap-
lotypes inferred by Phase v.2.1.45 POU5F1B diplotypes were
imputed with a probability R0.99 for 98% of the subjects. We
evaluated additive unconditional logistic regression models
adjusted for age to assess ORs, 95% confidence intervals, and
p values. An association between genotype and prostate cancer
was considered significant if the associated two-sided p value
was less than 0.05.
We performed expression quantitative trait locus-based (eQTL)
analyses by using themultilevel information provided in The Can-
cer Genome Atlas, adjusting for methylation status in normal and
tumor tissue and additionally for somatic copy number in tumor
tissue. We used multiple linear regression to compute the residual
expression not accounted for by methylation (normal or tumor)
and somatic copy number (tumor).We then regressed on the resid-
ual expression against the germline variants. As described in Li
et al., this separately estimates the effects of germline variants,
methylation status, and somatic copy number changes on expres-
sion level.46 These tests selectively evaluated the four independent
prostate cancer GWAS SNPs of the 8q24 locus for which TCGA
PRAD samples had existing data (rs13252298, rs16901979,
rs6983267, and rs4242384), the four 8q24 genes with existing
RNA-seq expression level data (POU5F1B within the 8q24 locus
and FAM84B, MYC, and PVT1 flanking the locus), and RNA-seq
expression level data of POU5F1 on 6p21. Fold changes in gene
expression between tumor and normal tissue in the same patients
were assessed by the sign test.Results
8q24 GWAS SNPs Are cis-Acting eQTLs that Modify
POU5F1B Expression in Normal Prostate
In normal prostate tissue of TCGA subjects, expression of
POU5F1B and PVT1 were significantly correlated (p ¼
0.004, R2 ¼ 0.18), as was their methylation state (p ¼
0.001, R2 ¼ 0.20). By contrast, expression of other gene
pairs among FAM84B, POU5F1B, MYC, and PVT1 were
not correlated in normal prostate. Of the four indepen-
dent prostate-cancer-associated risk SNPs identified in
prior GWASs with existing TCGA data (rs13252298,
rs16901979, rs6983267, and rs4242384), none were signif-
icantly correlated with expression of FAM84B, MYC, or
PVT1 among white subjects or among subjects of all racial
groups combined after adjustment for methylation status.The AmeHowever, two of the GWAS SNPs (rs13252298 and
rs6983267) were significantly associated with POU5F1B
expression in normal prostate tissue of white subjects
(p¼ 0.017 and 0.001, respectively) as well as that of all sub-
jects combined (p ¼ 0.054 and 0.018, respectively). Of the
two GWAS SNPs without significant correlation with
POU5F1B expression, rs16901979 has a low risk allele fre-
quency and limited power to detect association, whereas
rs4242384 was trending toward significance (p ¼ 0.056
among white subjects, p ¼ 0.083 among all subjects).
The risk alleles of these GWAS SNPs were consistently
accompanied by less POU5F1B expression whereas the pro-
tective alleles were accompanied by greater POU5F1B
expression in normal prostate tissue. Our results indicate
that these 8q24 GWAS SNPs are eQTLs influencing
POU5F1B expression in normal prostate tissue.
POU5F1B and POU5F1 Are Coexpressed in Normal
Prostate
Within normal prostate tissue, there was a significant
direct correlation between the expression of both POU5F1B
and PVT1 at 8q24 and POU5F1 at 6p21 (p ¼ 2.8 3 104
[R2¼ 0.34] and 0.001 [R2¼ 0.22], respectively). In contrast,
no significant correlation was observed between either
MYC or FAM84B expression and POU5F1 expression. The
risk allele of rs6983267 was significantly associated with
reduced POU5F1B (p ¼ 0.001) and POU5F1 (p ¼ 0.005)
expression in normal prostate of white subjects and was
trending for all subjects combined (p ¼ 0.018 and 0.127,
respectively). Among white subjects, the correlation be-
tween rs6983267 genotype and POU5F1 expression was
stronger for the shorter (less homologous) isoform 2 tran-
script (p ¼ 0.004) than for the longer isoform 1 transcript
(p¼ 0.032) fromwhich POU5F1Bwas originally retrotrans-
posed. The mean expression of isoform 1 was roughly half
as abundant as that of isoform 2. The expression means of
POU5F1B and of POU5F1were similar in normal tissue, and
64-fold less than that of MYC.
8q24 GWAS SNPs Do Not Modify POU5F1B Expression
in Prostate Tumors
Within prostate tumor tissue, FAM84B and MYC were
significantly coexpressed (p ¼ 2.3 3 1010 [R2 ¼ 0.21]).
POU5F1B and PVT1 were also significantly coexpressed
(p ¼ 1.03 1037 [R2 ¼ 0.61]) but unlike in normal prostate
tissue, they did not appear to be comethylated (p ¼ 0.197).
Among these genes no other pairs were significantly coex-
pressed. Given the close proximity of the genes, somatic
copy number changes within a given tumor altered them
jointly. Somatic copy number was directly correlated
with expression level of each gene. Methylation status of
each gene was inversely correlated with its expression,
with the exception of POU5F1B. Given the diverse tran-
scription start sites of POU5F1B, proximal methylation
status may not reflect distant methylation-sensitive regula-
tory sites well. None of the four GWAS SNPs was signifi-
cantly associated with the expression level of any of theserican Journal of Human Genetics 94, 395–404, March 6, 2014 397
Figure 1. POU5F1 versus POU5F1B Expression in Patients with
Both Normal and Tumor Prostate Tissue Data
Expression of these genes is positively correlated in both normal
and tumor tissue. There is somatic gain of POU5F1B and loss of
POU5F1 expression in tumors. Normal and tumor data points for
a given patient are designated by an interconnecting line.genes in prostate tumor tissue, although the risk allele
of rs6983267 trended toward greater MYC expression
(p ¼ 0.083 among white subjects, p ¼ 0.013 among all
subjects).
POU5F1B and POU5F1 Are Coexpressed in Prostate
Tumors
Within prostate tumor tissue, the expression of FAM84B,
POU5F1B, and PVT1 were each directly correlated with
the expression of POU5F1 (p ¼ 0.010 [R2 ¼ 0.05], 1.9 3
104 [R2 ¼ 0.10], and 0.012 [R2 ¼ 0.05], respectively,
among white subjects; p ¼ 0.088 [R2 ¼ 0.02], 3.6 3 105
[R2 ¼ 0.09], and 0.001 [R2 ¼ 0.06], respectively, among
combined subjects). The correlation between the expres-
sion of POU5F1B and the POU5F1 short isoform was stron-
ger than for the long isoform (p ¼ 1.03 104 versus 0.002,
respectively). MYC expression in prostate tumor tissue
also trended toward coexpression with POU5F1 (p ¼
0.044 [R2 ¼ 0.03] among white subjects; p ¼ 0.136 [R2 ¼
0.01] among all subjects).
POU5F1 Expression in Prostate Tumors Accompanies
Indices of Poor Prognosis
Elevated POU5F1 expression has previously been associ-
ated with a higher Gleason score47,48 as well as worse prog-
nosis for several cancer types.49 In TCGA data, POU5F1
(but not POU5F1B) expression level was also positively
associated with tumor Gleason score (p ¼ 0.032); this
was true of both the long and short isoforms (p ¼ 0.047
and 0.042, respectively). Overall, 11% of the tumors
gained R1 copy of the genes at 8q24, though lesser
measured gain was more frequent. 8q24 amplification
was associated with elevated Gleason score and increased
pathologic stage (p ¼ 7.6 3 105 and 0.041, respectively).
These replicate prior observations.50398 The American Journal of Human Genetics 94, 395–404, March 6Somatic Changes in Prostate Tumors Increase
POU5F1B and Decrease POU5F1 Expression
The transformation of normal to tumor is accompanied by
changes in POU5F1B and POU5F1 expression in opposite
directions. Among TCGA subjects with matching normal
and tumor data, POU5F1B expression was significantly
greater in prostate tumor relative to normal prostate (me-
dian 2.5-fold, p ¼ 3.0 3 104) whereas POU5F1 expression
was significantly lower (median 0.58-fold, p ¼ 0.005). By
comparison, median MYC expression increased 2.8-fold
(p ¼ 0.002). In both normal prostate and prostate tumor,
absolute MYC expression greatly exceeded POU5F1B
expression. In prostate tumors, the median expression
level of POU5F1B was 9.3-fold that of POU5F1. POU5F1B
expression in prostate tumor was significantly correlated
with somatic copy number (p ¼ 0.012 in all subjects; p ¼
0.021 in white subjects) but not with its methylation sta-
tus. The expression of POU5F1 also tended to be correlated
with somatic copy number (p ¼ 0.012 in white subjects;
p ¼ 0.098 in all subjects) but not with its methylation sta-
tus. Figure 1 shows expression levels for POU5F1B and
POU5F1 for patients for whom expression data was avail-
able from both normal and tumor tissue. This figure shows
that somatic gain of POU5F1B and loss of POU5F1 in pros-
tate tumors is not inconsistent with the observed positive
correlation of their expression.
Two SNPs Are Predicted to Be Deleterious in POU5F1B
We observed that GWAS SNPs detect regional eQTLs that
modify POU5F1B expression and alter risk of transforma-
tion of normal prostate. Two GWAS SNPs of the region
are in LD with SNPs within the POU5F1B ORF, which has
the potential to be translated. Given this, we evaluated
the possible association of POU5F1B genetic variation
with risk of prostate cancer. We sequenced unrelated sub-
jects of European descent within the Familial Prostate
Cancer Study, including 15 control subjects homozygous
for the protective allele of adjacent GWAS SNP rs6983267
and 54 case subjects carrying the risk allele (44 as homo-
zygotes, 10 as heterozygotes). Characteristics of these
subjects are detailed in Table S2. Although many of these
individuals were diagnosed at an early age and had strong
family histories of prostate cancer, we detected only com-
mon variation in the gene (variant frequencies are given
in Tables 2, S3, and S5). We identified ten SNPs in
POU5F1B, four of them potentially missense. If the tran-
script were translated, Polyphen-2 designates rs6998061
(Gly176Glu, POUS domain) as ‘‘possibly damaging’’ and
rs7002225 (Glu238Gln, POUH domain) as ‘‘probably
damaging,’’ whereas rs13273814 (Lys182Thr) and
rs13274084 (Asn214Asp) are ‘‘benign.’’51 SIFT predictions
are concordant, designating Gly176Glu and Glu238Gln
as ‘‘not tolerated.’’52 Figure S1 presents a multialignment
of Oct4 and Pou5F1b.
We genotyped the POU5F1B SNPs and a series of vali-
dated 8q24 GWAS risk SNPs in the Familial Prostate Cancer
Study (Table 2). GWAS SNPs rs6983267 and rs7000448, 2014
Table 2. Prostate Cancer Association of 8q24 GWAS SNPs and POU5F1B SNPs
Pairwise r2 SNP
SNP Allele,
Amino Acid
Encoded
Frequency
p OR 95% CICase Subjects Control Subjects
rs13252298* A 0.73 0.71 0.16 1.12 1.0–1.3
rs1016343* T 0.26 0.21 4.9 3 104 1.34 1.1–1.6
rs16901979* A 0.07 0.03 2.2 3 108 2.81 2.0–4.0
rs16902094* G 0.17 0.13 2.4 3 103 1.34 1.1–1.6
rs445114* T 0.66 0.62 0.014 1.20 1.0–1.4
rs6983267* T 0.43 0.50 5.0 3 105 0.76 0.7–0.9
rs4871022 T 0.56 0.58 0.25 0.92 0.8–1.1
rs4871789 G 0.49 0.50 0.47 0.95 0.8–1.1
rs75427380 C 0.98 0.99 – – –
rs6998061 A, 176Glu 0.37 0.43 3.6 3 104 0.78 0.7–0.9
rs13273814 A, 182Lys 0.81 0.80 0.77 1.03 0.9–1.2
rs13274084 A, 214Asp 0.89 0.87 0.17 1.16 0.9–1.4
rs6998254 A 0.49 0.50 0.54 0.96 0.8–1.1
rs7002225 C, 238Gln 0.49 0.50 0.53 0.96 0.8–1.1
rs79948117 C 0.76 0.77 0.53 0.95 0.8–1.1
rs77258034 A 0.65 0.64 0.66 1.03 0.9–1.2
rs7000448* C 0.61 0.66 5.5 3 103 0.82 0.7–0.9
rs1447295* A 0.14 0.09 6.3 3 106 1.67 1.3–2.1
Genotyped 8q24 SNPs include validated risk variants (marked with an asterisk [*]) and all detected SNPs at POU5F1B (on the LD block of rs6983267 and
rs7000448). SNPs rs4871022 through rs77258034 are within the POU5F1B transcribed region, and rs6983267 is 14.5 kb upstream. Missense SNPs are functional
candidates and demonstrate LD with additional noncoding SNPs. Values for r2 vary from 0 (white) to 1 (black).were both in LD with POU5F1B SNPs among subjects of
European descent. With the exception of rs13252298,13
all GWAS SNPs were significantly associated with prostate
cancer in single-allele association tests among the study
subjects of European descent (Table 1). Within POU5F1B,
only rs6998061 appeared significantly associated with
prostate cancer. GWAS SNPs rs6983267 and rs7000448
had greatest LD with rs6998061 (r2 ¼ 0.69 and 0.36,
respectively).
rs6983267 and Two Missense SNPs Mark POU5F1B
Haplotypes Altering Risk
More than 98% of the haplotypes of subjects of European
descent were among the eight depicted in Table 3. The
most common (haplotype A, harboring the potentially
deleterious mutations noted above) was associated with a
significantly decreased risk of prostate cancer. That haplo-
type was marked by the ‘‘protective’’ alleles of both GWAS
SNPs at the flanks of the LD block. The ‘‘risk’’ alleles of
those GWAS SNPs (asterisks) marked several common
haplotypes, but only haplotype B (harboring the POUH
domain alteration but not the POUS domain alteration)
was associated with an increased risk of prostate cancer
in the Familial Prostate Cancer Study population. This
led us to consider the possibility that the risk allele of eitherThe AmeGWAS SNP alone might not be sufficient to confer or
to detect the risk effect, or that the true effect detected
is that of the protective allele. The pair of predicted
deleterious missense SNPs, rs6998061 (Gly176Glu) and
rs7002225 (Glu238Gln), tagged the haplotypes identified
with potential risk effects.
Risk Effects Are Better Detected by the POU5F1B
Missense SNPs than the Correlated rs6983267
Given the LD patterns and potential for correlation of risk
effects, we evaluated logistic regression models to assess
adjusted effects of SNPs inLD in thePOU5F1B regionamong
subjects of European descent (Table 4). GWAS SNP
rs7000448 does not remain significant in a model with
GWAS SNP rs6983267. The risk signal it detects may be
due to LD with rs6983267, though pairwise LD is relatively
low (r2 ¼ 0.14). In a model including rs6983267 and all
four POU5F1B candidate missense SNPs, only POU5F1B’s
rs6998061_A and rs7002225_C are significant (p ¼ 0.001,
OR ¼ 0.49 [95% CI 0.3–0.8]; and p ¼ 6.9 3 105, OR ¼
1.73 [95% CI 1.3–2.3], respectively); GWAS SNP rs6983267
does not retain significance. When the model includes
only the two missense SNPs, stronger effects are observed
(p ¼ 2.0 3 108, OR ¼ 0.47 [95% CI 0.4–0.6]; and p ¼
9.43 106, OR ¼ 1.79 [95% CI 1.4–2.3], respectively).rican Journal of Human Genetics 94, 395–404, March 6, 2014 399
Table 3. Prostate Cancer Association with POU5F1B Haplotypes
Haplotype rs
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Frequency
p OR 95% CI
Case
Subjects
Control
Subjects
A T T G C A A A A C C A C 0.36 0.42 4.9 3 104 0.78 0.7–0.9
B G* T G C G A A A C C A T* 0.12 0.07 5.5 3 107 1.94 1.5–2.5
C G* C A C G A A G G C A T* 0.15 0.13 0.11 1.18 1.0–1.4
D G* C A C G A A G G G T C 0.14 0.14 0.67 0.96 0.8–1.2
E G* C A G G A A G G G T C 0.02 0.01 0.30 1.36 0.8–2.4
F G* C A C G C A G G G T C 0.08 0.06 0.16 1.21 0.9–1.6
G G* C A C G C G G G C T T* 0.04 0.05 0.61 0.92 0.7–1.3
H T T A C G C G G G C T T* 0.06 0.08 0.20 0.84 0.6–1.1
Risk alleles of GWAS SNPs rs6983267 and rs7000448 are marked with an asterisk (*), indicating several common haplotypes without significant risk effects.Risk Effects of the POU5F1B Missense SNPs and
rs6983267 Are also Correlated in Subjects of African
Descent
Among the limited number of subjects of African descent
of the Familial Prostate Cancer Study, GWAS SNP
rs6983267 and POU5F1B SNPs rs4871022, rs6998061,
and rs7002225 were significantly associated with prostate
cancer (p¼ 0.0018, 0.033, 0.0019, and 0.035, respectively).
The remaining GWAS SNPs (predominantly detected
in published studies of subjects of European descent)
were not. Details are given in Table S3. The three
POU5F1B SNPs demonstrated moderate pairwise LD with
rs6983267 (r2¼ 0.42, 0.55, and 0.28, respectively). Pairwise
LD was generally lower and the number of observed haplo-
types greater (Table S4) than observed among the subjects
of European descent. The risk effects of these SNPs were
correlated, becoming insignificant when adjusted for
each other. In a model including GWAS SNP rs6983267
and the POU5F1B missense SNPs, none retained signifi-
cance. In a model including rs6998061 and rs7002225,
only the former was significant (p ¼ 0.011, OR ¼ 0.30
[95% CI 0.1–0.8]). The effects of GWAS SNP rs6983267
and of POU5F1B missense SNPs were thus correlated
among subjects of African as well as those of European
descent. Haplotype A was also significantly inversely asso-
ciated with prostate cancer (protective) among subjects of
African descent (p ¼ 1.3 3 103, OR ¼ 0.19 [95% CI 0.1–
0.5]). Its frequency was only 4% among affected subjects
and 17% among control subjects (relative to 42% of con-
trol subjects of European descent). Haplotype B did not
have an appreciable risk effect among subjects of African
descent. The most consistent observation comparing the
two racial groups was the significant effect of the protec-
tive haplotype A, marked by the protective allele at
GWAS SNP rs6983267, that in turn was correlated with
relatively elevated POU5F1B expression in normal prostate
tissue in TCGA data.400 The American Journal of Human Genetics 94, 395–404, March 6The POU5F1B Missense SNPs Consistently Mark a
Haplotype of Protective Effect across Study
Populations
To assess further, we genotyped rs6983267, rs6998061,
and rs7002225 in an independent Finnish prostate cancer
study population. Each was again significantly associated
with prostate cancer (see Table S5). As in the other study
populations, the risk effects of these three SNPs were corre-
lated, becoming insignificantwhen adjusted for each other.
Tagged haplotype A was again inversely associated with
prostate cancer (p ¼ 6.2 3 103, OR ¼ 0.84 [95% CI 0.7–
1.0], see Table S6). The remaining tagged haplotypes were
not significant. The effect of the protective haplotype was
consistently observed across each of the study populations.Discussion
This study has uncovered evidence that POU5F1B, a retro-
gene derived from the POU5F1master embryonic stem cell
factor gene, is associated with prostate cancer. The POU5F1
retrotransposition event at 8q24 occurred in an ancestor
common to Hominidae, resulting in duplication of a
17 bp target sequence to either flank. The retrogene ORF
is intact in humans and chimpanzees, and the portion of
it sequenced to date in the gorilla genome is also intact.
POU5F1B retrogene sequence is also observed in Nean-
dertal and Denisova genomes. Given this conservation, it
may have a functional role.
The 8q24 locus has been detected in GWASs of multiple
cancers, most prominently prostate cancer. Within TCGA
data, we observed that risk alleles of GWAS SNPs of the
locus are correlated with less POU5F1B expression in
normal prostate tissue. This observation is consistent
with the posited role of 8q24 GWAS SNPs as genetic vari-
ants of transcriptional regulatory elements that can
modify expression of a regional gene(s) to influence cancer, 2014
Table 4. Prostate Cancer Risk Effects of POU5F1B Missense
Variants Are Correlated with Adjacent 8q24 GWAS SNPs
Effect of Adjusted for p OR 95% CI r2 D’
rs6983267_T rs7000448 1.2 3 103 0.78 0.7–0.9
0.14 0.53
rs7000448_C rs6983267 0.22 0.91 0.8–1.1
rs6983267_T rs6998061 0.06 0.79 0.6–1.0
0.69 0.94
rs6998061_A rs6983267 0.70 0.95 0.7–1.2
rs6983267_T rs7002225 1.0 3 106 0.63 0.5–0.8
0.46 0.68
rs7002225_C rs6983267 5.0 3 103 1.30 1.1–1.6
rs6998061_A rs7002225 1.7 3 108 0.47 0.4–0.6
0.75 0.99
rs7002225_C rs6998061 9.4 3 106 1.79 1.4–2.3risk.28–35We did not observe a significant correlation of the
GWAS SNPs with expression of the other regional genes
(including MYC) in normal prostate tissue. Overall, lower
POU5F1B expression in normal prostate tissue accompa-
nied GWAS SNP genotypes that are associated with
increased risk of transformation. In prostate tumor tissue,
these GWAS SNPs were not significantly associated with
expression of POU5F1B or the other regional genes. How-
ever, an association between rs6983267 and increased
MYC expression in prostate tumor tissue trended toward
significance.
Expression of POU5F1 is transcriptionally self-regulated
by the encoded Oct4 transcription factor.53,54 POU5F1B
expression was significantly positively correlated with
POU5F1 expression in both normal prostate tissue and
prostate tumors. rs6983267 genotype was significantly
correlated with both POU5F1B and POU5F1 expression in
normal prostate tissue. Our results identify these as cis and
trans eQTLs. We considered the possibility that paired-end
read misalignment within the TCGA data might confound
distinction of expression of the two genes. The RSEM algo-
rithm applied by the TCGA project had been specifically
selected to optimally quantify expression in just such a
scenario.55 Three observations suggest that the measures
are not significantly confounded. First, expression of the
POU5F1 isoform least homologous to POU5F1B was that
most significantly correlated with rs6983267 genotype.
Second, expression of POU5F1B in a given tumor increased
while that of POU5F1decreased.Neither observationwould
be expected if the TCGA expression measures were sig-
nificantly confounded. And third, the expression of PVT1,
a gene whose expression was correlated with POU5F1B
and iswithoutpossibility this potential sourceof confound-
ing, was also correlated with POU5F1 expression.
We found that the risk allele of rs6983267 marked
several common haplotypes encompassing the adjacent
gene POU5F1B. These haplotypes did not have consistent
risk effects either within or across the tested study popula-
tions. This observation was difficult to reconcile with the
notion that the risk allele of the SNP may be directly func-
tional as the source of the association signal. In contrast,
the protective allele of rs6983267 marked a haplotypeThe Amethat was consistently inversely associated with prostate
cancer risk among US study subjects of European descent,
US study subjects of African descent, and Finnish study
subjects. Although this protective haplotype was the
most common one in the subjects of European descent
(42% frequency in control subjects), it was notably less
common among those of African descent (17% frequency
in control subjects). Predicted deleterious alleles of two
POU5F1B missense SNPs, rs6998061 (glycine to glutamate
substitution Gly176Glu) and rs7002225 (glutamate to
glutamine substitution Glu238Gln) mark that haplotype.
In the POU5F1B region, the effect of the GWAS SNP
rs6983267 is correlated with the effects of these two
missense SNPs, the latter more directly detecting risk ef-
fects among US subjects of European descent.
Both our eQTL results and the risk association results
support POU5F1B as a plausible candidate gene at the
8q24 locus that could alter risk of transformation of
normal prostate tissue.40,41 Expression constructs can
produce a transcriptionally functional Pou5f1b protein
(Panagopoulos et al.39 evaluated Pou5f1b encoded by
haplotype D), but evidence for translation of the endoge-
nous POU5F1B transcript remains lacking. A structural
model of the predicted Pou5f1b protein is depicted in
Figure S2.56 If the POU5F1B transcript were not translated,
an alternative functional mechanism could be that of a
competing endogenous RNA.57 MIR145 (MIM 611795)
negatively regulates the transcripts of pluripotency factors
POU5F1 (MIM 164177), SOX2 (MIM 184429), and KLF4
(MIM 602253).58 The POU5F1B transcript 30 UTR retains
the target site for MIR145 (unaltered by SNPs).
Our study implicates a retrogene of a master embryonic
stemcell factor in the risk of transformation of normal pros-
tate tissue. A broader pattern of the association of genetic
variation in biological pathways underlying stem cells
with cancer may exist. Several studies have investigated
the role of NANOGP8 in cancer development, including
prostate cancer.59–71 GWAS SNPs in prostate cancer mark
additional embryonic stem (ES) cell-related genes. SNPs
in CTBP2 (MIM 602619) (ES overexpressed72 and Oct4
binding73), ZFHX3 (MIM 104155) (Oct4 binding73), and
ITGA6 (MIM 147556) (ES overexpressed72) are each noted
in prostate cancer GWAS publications, but not in the
context of stem cell function. Additional prostate cancer
GWAS SNPs are in the LD blocks of genes that are over-
expressed in ES cells72 (for example rs10934853,21
rs9623117,74 and rs575916720 of RUVBL1 [MIM 603449],
ADSL [MIM608222], andTTLL12, respectively). Sixpercent
of the SNPs that were nominally significant in stages I and
II of the Cancer Genetic Markers of Susceptibility GWAS
of prostate cancer14 reside within ES-cell-related genes
(those of Boyer et al.,53 Assou et al.,72 and Pardo et al.73)
(permutationp¼23105), and11%of the SNPs are inpair-
wise LD (r2R 0.2) with SNPs of these genes (permutation
p < 1 3 105). Further study of the role of POU5F1B and
of genetic variation of biological pathways underlying
stem cells in cancerous transformation is warranted.rican Journal of Human Genetics 94, 395–404, March 6, 2014 401
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